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Abstract
Recent years have seen major advances in the management of metastatic renal cell carcinoma (mRCC). The
tyrosine kinase and mammalian target of rapamycin inhibitors have resulted in disease control and improved
survival for many patients with mRCC, but they have not led to preventive, predictive or personalised medicine
(PPPM). Failure to achieve this rests ultimately with inadequate knowledge of tissue and molecular heterogeneity;
discovery of these drugs was based upon identification of pathogenic molecular pathways in RCC, but research
into molecular factors which underpin drug response, resistance and selection of therapy for individual patients has
lagged well behind clinical trials of drug development. This review will provide an overview of the development of
targeted drug therapies for mRCC, will discuss the challenges which currently impede the delivery of PPPM,
including identification of biomarkers, drug resistance and molecular heterogeneity, and will propose research
methodologies and technologies required to overcome these obstacles.
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Introduction
Renal cell carcinoma is a relatively rare cancer in which
prognosis is highly individual
Renal cell carcinoma (RCC) is an epithelial neoplasm
arising from the parenchyma of the kidney, which
accounts for 95% of renal neoplasms, and 3% of adult
malignancies [1]. RCC is a relatively rare cancer, with an
incidence of 60,000 cases in the European Union in
2006, but is associated with a high mortality rate; in the
same year, there were 26,000 deaths due to this disease
[2].
The prognosis in RCC has traditionally been thought
to be influenced by tumour stage, nuclear grade and his-
tologic tumour necrosis [3]. Those patients with disease
confined to the kidney and regional lymph nodes are
treated with nephrectomy (partial or radical) with cura-
tive intent. However, approximately one third of patients
have metastases at the time of diagnosis [4], and a simi-
lar proportion develop metastatic disease within 5 years
of follow up [5]. Common secondary sites include
lymph nodes, lung and bone.
Metastatic RCC is incurable
Metastatic RCC (mRCC) is incurable, and the aim of
therapy for patients with advanced disease is to control
the disease burden for as long as possible, thus amelior-
ating the patient’s symptoms and improving quality of
life, and prolonging overall survival time. Nephrectomy
is still considered standard treatment for those patients
who have a good performance status and a limited bur-
den of metastatic disease, based on the results of two
randomised studies which found a survival benefit for
patients treated with nephrectomy and cytokine therapy,
compared with cytokine therapy alone [6]. Historically,
patients with mRCC have had extremely limited sys-
temic treatment options and poor 5 year survival rates.
Hormone therapy and chemotherapy produce response
rates of 10% or less [7,8]. Cytokine therapy, including
interferon alfa and high dose interleukin-2, may benefit
a small proportion of patients, resulting in response
rates of 10-20%, and a modest survival benefit of several
months over non-immunotherapy controls [9,10]. A
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interleukin-2 therapy. Despite the recent SELECT trial
demonstrating a response rate of 29% to interleukin-2
[11], there are still no established criteria to select those
patients who will benefit from immunotherapy, and
these treatments have been associated with substantial
toxicity. Thus, an accurate risk-benefit analysis for an
individual patient is difficult.
Shifted focus of drug development
In the last decade, drug development in oncology has
shifted its focus from cytotoxic treatments toward biolo-
gical therapies. The use of ‘targeted’ therapies is depen-
dent on the identification of biological pathways that
selectively confer a growth and/or survival advantage to
the cancer cell. There are many examples of drugs
which attempt to exploit the underlying biology of the
tumour, including trastuzumab, used in Her-2 amplified
breast cancer [12,13], the tyrosine kinase inhibitors ima-
tinib for chronic myeloid leukaemia [14], and erlotinib
and gefitinib in non-small cell lung cancer [15,16]. More
recently, breakthroughs have occurred in two refractory
tumours with the development of vemurafenib for
BRAF-mutant melanoma [17] and crizotanib in patients
with non-small cell lung tumours with rearrangement of
the ALK gene [18]. Arguably, however, renal cell cancer
is the solid tumour type that has enjoyed the most suc-
cess from a targeted approach to therapy, and has the
most number of biological agents available for clinical
use. Six agents are now approved for mRCC, which tar-
get pro-angiogenic and proliferative pathways; the small
molecule tyrosine kinase inhibitors sunitinib, sorafenib,
and pazopanib, the monoclonal antibody bevacizumab,
and the mammalian target of rapamycin (mTOR) inhibi-
tors temsirolimus and everolimus. As a result, the prog-
nosis for patients with mRCC has improved
dramatically, and clinicians hope that mRCC may yet
become a ‘chronic disease’ [19].
RCC is characterised by much heterogeneity
Despite these advances, mRCC is a diverse disease with
much clinical, pathological and molecular heterogeneity.
This argues strongly for an individualised approach to
therapy, but a number of obstacles stand in the way of
preventive, predictive and personalised medicine for this
condition. This review will discuss the pathological and
molecular subtypes of RCC, the heterogeneity in clinical
course and the role of systemic therapy in this context,
and propose mechanisms by which tailored therapy for
patients might be achieved.
Pathological and molecular classification of RCC
The 2004 WHO classification system identifies distinct
histological subtypes of RCC [20]; the major subtypes
are clear cell, papillary types 1 and 2, chromophobe, and
collecting duct cancers. Translocation and medullary
tumours and mucinous tubular and spindle cell carcino-
mas are rare entities. The various subtypes are asso-
ciated with diverse clinical outcomes, and distinguishing
between them may provide a useful indication of prog-
nosis, and guide to appropriate therapy, for an indivi-
dual patient.
Clear cell RCC
Clear cell RCC accounts for approximately 75% of
malignant kidney tumours, and 90% of RCCs that
metastasise [21]. So called ‘conventional’ clear cell RCCs
are recognised histologically by clear cell cytoplasm;
morphological variants include granular and sarcoma-
toid carcinomas. Clear cell RCC can be diagnosed from
hematoxylin and eosin-stained microscopy, but they are
also associated with a typical immunohistochemical pat-
tern with positivity for vimentin, cytokeratin, and CA-IX
[21,22]. Genetically, clear cell RCC is characterised by
loss of DNA in the short arm of chromosome 3 (3p),
which has been shown to occur in 79-90% of cases, as
detected by FISH [23]. This region contains the Von
Hippel-Lindau (VHL) gene, a tumour suppressor
thought primarily responsible in the pathogenesis of
hereditary and sporadic clear cell RCC. Inactivation of
VHL, due to somatic mutation, or hypermethylation,
occurs in 100% of familial RCCs as part of VHL disease,
and in up to 80% of sporadic clear cell tumours [24,25].
The VHL protein (pVHL) regulates hypoxia-inducible
factor (HIF) by ubiquitin-mediated destruction [26,27]
and in the absence of functional pVHL, HIF activates a
number of hypoxiaresponse genes such as vascular
endothelial growth factor (VEGF), erythropoietin (Epo),
platelet derived growth factor (PDGF), TFG-a and -b,
all of which are associated with tumour angiogenesis
and growth [28-30]. HIF gene expression is also
increased by activation of mTOR, part of the complex
PI3 kinase/Akt pathway, thereby contributing to angio-
genesis [31], but this pathway also appears to be critical
in promoting in cell growth and survival [32]. A point
mutation in mTOR, R2505P, has been identified in renal
cell carcinoma, and confers constitutive activation of
mTOR signalling [33].
Epigenetic mechanisms, such as DNA methylation and
modification of histone proteins, also control gene
expression and have an important role in human can-
cers. Amongst other functions, both of these processes
regulate chromatin structure, and are thereby implicated
in transcriptional control [34]. Several studies have iden-
tified a number of chromatin modifying genes which
appear to be closely related to this disease. The histone
demethylases JMJD1A and JMJD2B have been recog-
nised as transcriptional targets of HIF-1, and have
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functional VHL protein [35,36]. A large-scale screen of
coding exons of 3544 genes in 101 clear cell RCCs iden-
tified activating mutations in SETD2 and JARID1C,b o t h
encoding enzymes in histone modification, and muta-
tions in the histone demethylase UTX [37]. However,
collectively these mutations are thought to occur in less
than 15% of clear cell RCC, and most recently, truncat-
ing mutations in the chromatin remodelling complex
gene PBRM1 were found in 41% (92/227) of clear cell
RCC cases [38]. Data suggest that PBRM1 is the second
major tumour suppressor cancer gene associated with
clear cell RCC after VHL, regulating pathways associated
with chromosomal instability and cellular proliferation.
Notably, VHL, PBRM1 and SETD2 genes all map to
chromosome 3p and it is speculated that physical link-
age and possibly interaction of these three genes are the
key drivers for the 3p loss of heterozygosity commonly
seen in clear cell RCC.
Papillary RCC
Papillary RCC (pRCC) comprises approximately 15% of
malignant kidney tumours. This subtype is further clas-
sifed into types 1 and 2, which are morphologically and
biologically distinct [39]. Most of these (60-70%) are
type I papillary tumours, which are generally considered
to be low grade and are more frequently multifocal [40].
Hereditary papillary renal carcinoma (HRPC) is asso-
ciated with activating mutations in the MET gene on
chromosome 7 [41]; this oncogene encodes a membrane
tyrosine kinase receptor whose ligand is hepatocyte
growth factor (HGF). Multiple downstream signalling
pathways of the receptor, including P13K, influence cell
proliferation, survival and mortality [41,42], and consti-
tutive activation of the network may therefore lead to
carcinogenesis. The mutation in MET has also been
identified in a small proportion of patients with sporadic
type I pRCC [43], but inactivation may occur via epige-
netic mechanisms with much higher frequency [44].
Type 2 pRCC, accounting for 30-40% of papillary
tumours, also occurs in hereditary and sporadic forms.
However, in contrast to Type 1 pRCCs, these tumours
are more likely to be high grade and cytogenetically
complex, and are therefore associated with a poor prog-
nosis. Patients with hereditary leiomyomatosis and RCC
(HLRCC) have a mutation in the gene encoding the
Krebs cycle enzyme fumarate hydratase (FH), and are at
risk of developing cutaneous and uterine leiomyomas
and an aggressive phenotype of type 2 pRCC [45].
Another familial form of RCC results from germline
mutation of succinate dehydrogenase B (SHDB) [46]; FH
and SHDB appear to be tumour suppressor genes in
which mutations cause increased levels of Krebs cycle
enzymes fumarate and succinate respectively. Similar to
the pathogenic role of mutations in the isocitrate dehy-
drogenase metabolic enzymes (IDH1 and IDH2) in some
gliomas, these mutant metabolic enzymes inhibit prolyl-
hydroxylases in the cell cytosol, which leads to stabilisa-
tion of HIF1-alpha and activation [47-49]. Dysregulation
of other cell signalling pathways, such as the MYC path-
way, may also be relevant in high grade, aggressive type
2 pRCC [50].
Chromophobe RCC
Five to ten percent of RCCs are chromophobe renal cell
carcinomas (ChRCC), which can be difficult to distin-
guish histologically from renal oncocytoma, a benign
neoplasm. However, ChRCC is usually associated with
complex loss of multiple chromosomes as detected by
FISH [51] and newer gene expression profiling techni-
ques have identified the genes CD82 and S100A1 and
AQP6 which are expressed differentially on ChRCC and
oncocytomas respectively [52]. Several studies have
reported upregulation of KIT, a membrane receptor tyr-
osine kinase, and have suggested that overexpression
m a yp l a yap a t h o g e n i cr o l ei nC h R C C[ 5 2 - 5 4 ]b u ti t s
therapeutic relevance is not yet certain.
Rare subtypes
The remaining RCC subtypes are rare, and less is known
of their molecular characteristics. Collecting duct carci-
nomas, despite being of the same embryological origin
as the ureter, do not necessarily share the same molecu-
lar abnormalities that characterise urothelial carcinomas.
Loss of chromosome 8p in collecting duct tumours has
been identified and may be associated with a worse
prognosis [55]. The genetic anomalies seen in mucinous
tubular and spindle cell carcinoma (MTSCC), a low
grade tumour, are heterogenous and require further
investigation [56,57]. Xp11 translocation tumours were
first included in the WHO classification in 2004, and
usually affect children and adolescents [58,59]. These
tumours have a unique histological appearance and are
characterised by a breakpoint at chromosome Xp11 and
gene fusions between TFE3 transcription factor and
multiple genes [60].
Clinical patterns in mRCC
mRCC is associated with significant inter-individual var-
iation in clinical course. Prognosis is often influenced by
the histological subtype although this is yet to be fully
established. Overall, papillary and chromophobe RCC
are thought to portend an improved prognosis com-
pared to clear cell RCC [61], but there are data to sug-
gest these tumours are more resistant to treatment and
are associated with poorer survival once they have
metastasised [62]. Collecting duct tumours and those
with sarcomatoid features behave more aggressively
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and less than 9 months respectively [62,63].
Furthermore, it is apparent to clinicians who treat
mRCC that there is marked clinical heterogeneity even
within a particular subtype. It is well recognised that a
subset of patients with mRCC has an indolent disease
course, and many attempts have been made to charac-
terise this group, and to develop methods of predicting
the outcome for an individual patient. However, it
seems likely that this observation is the result of signifi-
cant genetic heterogeneity which exists within a histo-
pathological subtype, even when this subtype appears to
be dominated by mutations in a single gene. This het-
erogeneity was clearly demonstrated in the earlier
described gene sequencing studies in clear cell RCC
[37].
The model most widely used to predict clinical out-
comes in mRCC is that defined by the Memorial Sloan
Kettering Cancer Center (MSKCC) [9]. A retrospective
analysis grouped patients treated in clinical trials of
cytokines into favourable, intermediate and poor risk
categories on the basis of five factors predictive of short
survival; interval from diagnosis to treatment of less
than 1 year, Karnofsky performance status less than
80%, elevated serum lactate dehydrogenase (LDH),
hypercalcaemia and anaemia. This model was validated
in an independent cohort of treatment-naive patients,
and prior radiotherapy and sites of metastasis were also
identified as negative prognostic factors [64]. Several
models have been described for use in patients treated
with tyrosine kinase inhibitors. Patient outcomes from
the phase III, landmark trial of sunitinib versus inter-
feron were analysed and 11 pre-treatment factors were
used to develop a nomogram which predicts the prob-
ability of 12 month progression free survival [65]. This
tool is clearly restricted to those treated with sunitinib
and may not be generalisable to patients outside a clini-
cal trial; it also requires independent validation. Heng et
al. reported that components of the MSKCC model are
valid in patients treated with VEGF-targeted therapy
(anaemia, hypercalcaemia, Karnofsky performance status
and time from diagnosis to treatment of less than 1
year) and added platelet and neutrophil counts as inde-
pendent adverse prognostic factors [66]. This analysis
was based on a heterogeneous patient population and
the authors argue that is widely applicable to patients
treated in the kinase inhibit o re r a .H o w e v e r ,a l lo ft h e
models described above are limited on the basis of ret-
rospective analyses and their utilisation of pre-treatment
risk factors only.
Prognostic models such as these have been used to
select those patients with an improved risk profile who
may benefit from alternatives to systemic therapy. For
example, it is common clinical practice to observe
patients with indolent, asymptomatic metastatic disease
and a recent retrospective review confirmed that this
strategy may be reasonable for some patients, although
the selection criteria are yet to be defined, and prospec-
tive confirmatory data are required [67]. Surgical resec-
tion of metastatic disease is another therapeutic option,
particularly historically when there was a lack of effec-
tive systemic therapy. Anecdotal reports of metastasect-
omy resulting in long term survival date back to 1939
[68], and 5 year survival rates associated with complete
resection of metastases ranged between 35 and 60%
[69]. Recently, Alt et al. reported on the survival of 887
patients treated with nephrectomy, who subsequently
developed metastases [70]. Of these, 124 patients under-
went surgical resection of all metastases and had a med-
ian 5-year cancer specific survival rate of 32.5%,
compared to 12.4% for those patients who did not
undergo metastasectomy. Outcomes were further
improved in patients with lung-only metastases, who
had a 5-year cancer specifics u r v i v a lr a t eo f7 3 . 6 %i f
completely resected. There are also recent reports of
patients achieving durable complete responses through a
combination of systemic anti-angiogenic therapy and
subsequent metastasectomy [71,72]. Surgical series of
patients with mRCC are small with a heavy selection
bias; nevertheless, when complete histological resection
is achieved, metastasectomy for some individuals anec-
dotally improves survival, and may be curative in a min-
ority. Surgery to remove metastases may also provide
effective symptom palliation, and in the setting of oligo-
metastastic disease, it might obviate the need for sys-
temic treatment, which is usually associated with side
effects. Again, there is no robust evidence to guide
selection of patients for surgery, and the optimal timing
of surgery and integration of treatment modalities in the
targeted therapy era are unknown.
Systemic therapy for mRCC and personalised
medicine
Systemic treatments used in mRCC
As discussed previously, cytotoxic and hormonal thera-
pies have had a limited role in the treatment of mRCC,
and until 2005, immunotherapy was the treatment of
choice, despite providing clinical benefit for only a min-
o r i t yo fp a t i e n t s .S i n c e2 0 0 5 ,an u m b e ro fn e wa g e n t s
have been developed and approved for use in this dis-
ease with substantial improvements in patient outcomes.
Broadly, current treatments can be classified as anti-
VEGF agents, mTOR inhibitors, immunotherapy and
cytotoxics.
Sunitinib is an oral inhibitor of multiple receptor tyro-
sine kinases (RTKs), including VEGFR, PDGFR, FLT-3
and c-KIT [73,74]. The phase III trial of sunitinib versus
interferon, in patients with untreated, clear cell mRCC,
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treatment, with a median progression free survival time
of 11 months for patients treated with sunitinib, com-
pared with 5 months for those treated with interferon.
A statistically significant difference in overall survival
was found when patients who crossed over from inter-
feron to sunitinib (approximately 1/3 of those rando-
mised) were excluded from the analysis [75]. These
results were confirmed in a broader mRCC population
in an expanded access trial [76]. Sorafenib is also an
orally administered multi-targeted tyrosine kinase inhibi-
tor (TKI), inhibiting VEGFR-2 and -3, PDGFR, FLT3,
cKIT, RET, BRAF and CRAF [77], and also resulted in
an approximate doubling of median progression free
survival times compared with placebo in patients who
had progressed after first line cytokine therapy; median
PFS for sorafenib was 5.5 months compared with 2.8
months in the placebo group [78]. Again, overall survi-
val results were confounded by patient crossover from
placebo to sorafenib. A third drug in this class is pazo-
panib, a second generation TKI targeting VEGFR-1, -2
and -3, PDGFR and cKIT; in particular, preclinical stu-
dies established it as very potent inhibitor of VEGFR-2
[79]. Based on a randomised phase III trial, pazopanib
appears to have similar efficacy to sunitinib in the first
line treatment of mRCC, with a median PFS of 9.2
m o n t h s ,c o m p a r e dt o4 . 2m o n t h sf o rp l a c e b o - t r e a t e d
patients [80], and an overall survival difference of 2.4
months in favour of pazopanib [81]. Results of a phase
III trial directly comparing sunitinib and pazopanib are
awaited.
The mammalian target of rapamycin (mTOR) is a
non-receptor tyrosine kinase in the PI3K-Akt pathway.
Activation of mTOR has multiple downstream conse-
quences including upregulated HIF expression [31] and
effects on intracellular signalling pathways involved in
cell growth and proliferation [82,83]. The mTOR inhibi-
tors, temsirolimus and everolimus, bind to FK506-bind-
ing protein (FKBP) and this protein-drug complex
inhibits the kinase activity of the mTOR complex 1
(mTORC1) [84]. Disruption of mTOR signalling results
in reduced translation of cell cycle regulatory proteins,
such as D-type cyclins, c-myc and p27
kip-1 [85], and
suppressed angiogenesis [86,87] (Figure 1). Temsiroli-
mus, an intravenously administered mTOR inhibitor,
significantly prolonged median overall survival in
patients with untreated, poor-risk mRCC, when com-
pared with interferon, or the combination of inter-feron
and temsirolimus in a phase III trial (10.9 months for
temsirolimus, 7.3 months for interferon, and 8.4 months
for the combination) [88]. Everolimus is an oral mTOR
inhibitor and was established as the standard of care for
second line treatment after failure of VEGF-directed
TKI therapy following a phase III trial in which
everolimus treatment resulted in significantly prolonged
progression free survival compared to placebo [89].
Bevacizumab is a humanised monoclonal antibody
against VEGF. A randomised phase II trial established
that it had clinically meaningful activity in patients with
mRCC [90] and two independent phase III trials com-
bined bevacizumab with interferon-a in an attempt to
improve its efficacy [91,92]. Both studies reported
improved progression free survival with combination
treatment compared to interferon alone, and justify the
use of this combination in first line therapy of meta-
static RCC in intermediate- and good-risk patients.
However, neither trial observed a difference in overall
survival from the addition of bevacizumab, possibly
because the majority of patients in both studies received
subsequent, second-line therapy which included VEGF-
targeted treatments.
Immunotherapy and cytotoxic agents are no longer
considered standard therapies in mRCC. However, the
regimen of capecitabine and gemcitabine chemotherapy
has demonstrated activity in mRCC [93-96], and there is
a recent report of two patients with prolonged remis-
sions after treatment with this combination, and in the
setting of failed targeted therapy [97]. There are also
encouraging early results from a novel immunotherapy,
anti-PD-1 (MDX-1106), which acts to enhance anti-
tumour T-cell response [98]. PD-1 is a so called
‘immune checkpoint molecule’ found on activated T, B
and myeloid cells, whose ligand is B7-H1–the interac-
tion between PD-1 and B7-H1 down-regulates T cell
activation [99] (Figure 2). B7-H1 is constitutively
expressed in many human carcinomas but not in normal
tissues [100] and expression of B7-H1 in nephrectomy
specimens has been associated with a worse prognosis
in patients with RCC [101].
It is important to note that patients with non-clear
cell mRCC have been largely excluded from the pivotal
clinical trials of the newer agents, apart from the rando-
mised study of temsirolimus [88] and the expanded
access trials of sunitinib and sorafenib [76,102]. The lar-
gest retrospective series of patients with papillary or
chromophobe mRCC treated with sunitinib or sorafenib
demonstrated that there was clinically meaningful activ-
ity of these agents for some individuals, but that this
was lower than that observed in patients with clear cell
mRCC [103]. Subset analyses of the phase III temsiroli-
mus trials suggest greater benefit of temsirolimus (rela-
tive to interferon) in patients with non-clear cell mRCC
[104,105]. A prospective phase II trial examining the
response rate to sunitinib in papillary mRCC found it
was significantly lower in these patients compared with
clear cell patients [106], but further data on the efficacy
of anti-VEGF and mTOR treatments in non-clear cell
histologies from phase III trials are awaited.
Fisher et al. The EPMA Journal 2012, 3:1
http://www.epmajournal.com/content/3/1/1
Page 5 of 14Personalised systemic therapy in mRCC
Despite clear advances in the treatment of mRCC with
the development of the above-mentioned drugs, mole-
cularly directed personalised medicine approaches for
this condition have not been achieved. There are no
established criteria by which to select one treatment
over another for an individual patient, apart from clini-
cal factors such as the desire to have oral rather than
intravenous therapy, and patient co-morbidities and
performance status. Equally important is the lack of
predictors of response or resistance to therapy. This is
in obvious contrast to other tumour types, such as
lung, breast, and colorectal cancers, and now mela-
noma, in which biomarkers are used routinely to pre-
dict response to treatment. Biomarkers can be defined
as molecular, cellular or functional measurable para-
meters indicative of important clinical events such as
cancer onset, recurrence, progression or death [107].
The fact that none have been identified for use in
mRCC may be because agents such as sunitinib act on
non-tumour components such as the endothelium,
rather than on the tumour cell itself [108], but may
also reflect a lack of systematic tissue collection in the
drug development trials for mRCC to date. None of
the phase III trials of the drugs currently in use for
mRCC included mandatory tissue collection in their
protocols, and no prospective translational endpoints
were included in these studies. Another issue unique
to RCC and which impedes the identification of bio-
markers is its marked tissue heterogeneity. Biomarker
discovery trials to date have been based on the
assumption that a single biopsy reflects the somatic
mutation landscape of the tumour, but variation of
growth pattern and cytological features are frequently
Figure 1 The mTOR signalling pathway. The mTOR response to growth factors is controlled by the PI3K pathway. Activation of the PI3K-Akt
pathway is opposed by PTEN, a tumour suppressor. Raptor and rictor interact with mTOR to form the mTORC1 and mTORC2 complexes
respectively, which mediate downstream signalling. Phosphorylation of the mTORC1 targets, ribosomal protein S6 (p70) kinases and eIF4Ebinding
proteins (4E-BPs), results in promotion of mRNA translation, stimulation of protein synthesis and entry into the G1 phase of the cell cycle. The
rapamycin-insensitive mTORC2 complex functions to regulate Akt and the cytoskeleton.
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tiple areas within the same lesion would be required to
assess the extent of molecular heterogeneity [109].
Candidate biomarkers in RCC
Research into potential biomarkers for mRCC has
focussed on the clear cell subtype, because it is the
dominant histological type, but also because the molecu-
lar pathogenesis has been well defined. In almost all
cases of clear cell RCC there is loss of function of the
VHL tumour suppressor gene, yet VHL gene status has
not been reliably demonstrated to have prognostic or
predictive value. Choueiri et al. demonstrated a differen-
tial response rate in 123 patients with clear cell mRCC
treated with anti-VEGF therapy (sunitinib, sorafenib,
axitinib or bevacizumab) according to VHL status [110].
Those patients with inactivated VHL, defined by muta-
tion or methylation, had a similar response rate to those
with wild-type VHL (41%, compared to 31%). Those
w i t hal o s so ff u n c t i o nm u t a t i o ni nV H Lh a dah i g h e r
response rate of 52%, but this did not translate into
improved progression-free or overall survival. Obvious
limitations of this analysis are its retrospective nature
and differences in the treatments given, and the overall
survival data were immature at the time of publication.
The improved response rates were not confirmed by
two further studies; in 13 patients treated with axitinib,
and in 78 patients treated with pazopanib, there was no
relationship between VHL gene status and response
[111,112].
HIF plays a critical role in the VHL pathway as a tran-
scription factor for angiogenic genes in the absence of
functional VHL protein. It consists of two alpha subu-
nits (HIF-1 alpha and HIF-2 alpha) and one stably
expressed beta subunit. The two alpha subunits are
thought to have similar but not fully redundant func-
tions, and it has been suggested that HIF-2-alpha may
be more important than HIF-1-alpha in angiogenesis
[113]. Gordan et al. distinguished two types of VHL-
deficient clear cell RCC; those that express HIF-1-alpha
and those that do not [114], but the clinical relevance of
this remains to be determined and there have been con-
flicting results from studies examining HIF-1-alpha
expression as a prognostic biomarker [115-118]. In a
retrospective study of archival tissue from 43 patients
with clear cell mRCC treated with sunitinib, high pre-
treatment levels of HIF-1-alpha or HIF-2-alpha pre-
dicted sensitivity to treatment but these results require
prospective validation [119].
Two of the many HIF-responsive genes, VEGF and
CAIX, have also been explored as potential biomarkers
in mRCC. The VEGF family is a key mediator of angio-
genesis and comprises multiple VEGF ligands, and three
cognate tyrosine kinase receptors. In the phase III trial
comparing sorafenib with placebo (TARGET trial), base-
line plasma levels of VEGF were available for 712
patients. Retrospective exploratory analysis revealed that
high baseline VEGF levels were associated with reduced
overall survival, but there was no relationship demon-
strated between changes in VEGF and soluble VEGF
receptor 2 (sVEGFR-2) levels during treatment and
patient outcomes [120]. Pre-treatment serum VEGF
l e v e l sw e r ea l s os h o w nt ob ep r o g n o s t i ci nas t u d yo f
302 patients with mRCC enrolled in cytokine clinical
trials [121], but were not predictive of response to beva-
cizumab in patients treated in the AVOREN study
[122]. However, Rini et al. demonstrated that baseline
Figure 2 Model of immune checkpoint molecules and T cell function. Inhibitory T cell co-receptors such as CTLA-4 and PD-1 cause T cell
anergy and apoptosis, impeding anti-tumour immunity. Abbreviations: B7H1/PD-L1 and B7H1/PD-L2 ligands for PD-1; PD-1 programmed death-1;
MHC II major histocompatability complex class II.
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VEGF-C levels correlated with improved response rates
and longer progression-free survival times in patients
treated with suni-tinib [123]. Two small phase II studies
of sunitinib and pazopanib in mRCC also suggest a
potential role for VEGF and the soluble forms of the
VEGF receptor as predictive biomarkers; the first study
found that significantly larger reductions in VEGF,
sVEGFR-2 and sVEGFR-3 levels occurred in patients
exhibiting an objective response to sunitinib, and in the
second, decreases in sVEGFR-2 were significantly corre-
lated with tumour response [112,124]. Given these con-
flicting results, the clinical utility of the VEGF family as
predictive biomarkers is uncertain.
Similarly, studies evaluating the potential of CAIX as a
biomarker in mRCC are hypothesis-generating only.
CAIX is a surface transmembrane enzyme that is highly
expressed in advanced RCC but not in normal kidney
tissue [125]. In several studies, tumours with low CAIX
staining by immunohistochemistry were associated with
worse clinical outcomes [125,126], but the largest series
which examined 730 clear cell RCC specimens, reported
by Leibovich et al., did not validate these findings [127].
There is limited evidence from two small studies to sug-
gest that high tumour CAIX staining may be a useful
predictor of benefit from interleukin-2 immunotherapy
[128,129] and is currently under evaluation by the Cyto-
kine Working Group in the SELECT trial. CAIX does
not appear to be predictive of response to sunitinib, sor-
afenib or temsirolimus [120,130].
Neutrophil gelatinase-associated lipocalin (NGAL) has
shown promise as predictive biomarker for mRCC
patients treated with sunitinib. NGAL is a protein that
is present in low levels in some human tissues, but is
induced by epithelial damage in the kidney, colon, liver
and lung [131]. It is a marker of acute and chronic kid-
ney injury [132,133] and is elevated in a number of can-
cers, when it is usually associated with a poor prognosis
[134]. It may be complexed with matrix metalloprotei-
nase-9, which plays a role in invasion and metastasis.
Porta et al. compared the predictive value of the Motzer
scoring system with baseline serum concentrations of
VEGF and NGAL in a cohort of 85 patients treated with
sunitinib [135]. Both biomarkers correlated significantly
with progression-free survival, whereas MSKCC score
did not. Patients classified as having high levels of VEGF
or NGAL (according to a threshold defined by the man-
ufacturer of the ELISAs used) had a relative risk of pro-
gressing of 2.14 and 1.86 respectively, compared to
patients with normal levels.
Components of the mTOR pathway have been evalu-
ated as potential biomarkers in mRCC. Constitutive acti-
vation of the mTOR kinase via the PI3K and AKT
signalling network results in activation of substrates,
such as the ribosomal subunit S6 kinase (S6K) and
eukaryotic initation factor 4E, which are critical for
s y n t h e s i so fp r o t e i n si n v o l ved in cellular growth and
survival. Activation of the AKT pathway can occur
through homozygous loss of the PTEN tumour suppres-
sor gene, but there is no definite prognostic significance
for PTEN loss in mRCC [136,137], and there does not
appear to be a correlation between tumour PTEN
expression and benefit from temsirolimus [138]. There
are also conflicting results for phosphorylated AKT
(pAKT) as a prognostic biomarker [136,137]. However,
Cho et al. found a positive association between phos-
phorylated S6 (pS6) expression and a trend towards
positive expression of pAKT with response to temsiroli-
mus [130]. Elevated lactate dehydrogenase (LDH) also
appears to predict for an increase in overall survival
with temsirolimus in poor-risk patients treated with
temsirolimus [139]. LDH is a serum enzyme, which is
regulated by the PI3K-Akt-mTOR pathway and tumour
hypoxia. It is elevated in many cancers, and has prog-
nostic significance in RCC. In this study of 404 patients
treated with temsirolimus or interferon, there was a sig-
nificant increase in patients with an elevated LDH trea-
ted with temsirolimus (n = 140), but in patients with a
normal LDH (n = 264) there was no survival difference
between temsirolimus and interferon treatments.
There is an emerging role for genetic biomarkers in
prognostication in mRCC. Traditional cytogenetic karyo-
typing studies have demonstrated loss of 3p, 4p, 9p and
14q as possible prognostic genetic biomarkers in mRCC
[140], but modern techniques such as gene expression
profiling and single nucleotide polymorphism (SNP)
genotyping seem more likely to be able to pinpoint spe-
cific carcinogenetic events or predict outcomes from
treatment. Two studies analysing gene expression pro-
files in clear cell RCC have identified panels of candi-
date genes that appear to correlate strongly with
survival and recurrence-free interval [141,142]. The first
study of 177 clear cell tumours classified tumours into
two subsets, defined by a set of gene features, each with
distinct prognoses and biological behaviours. The sec-
ond study is the largest genomic series to date, and ana-
lysed 931 archival specimens from the Cleveland Clinic
by RT-PCR for expression of 727 genes (including 5
reference genes). Sixteen genes were identified as
strongly associated with recurrence-free interval, and
interestingly, among these 16 genes, increased expres-
sion of angiogenesis and immune-related genes corre-
lated with a lower risk of recurrence, whereas a higher
risk of recurrence was demonstrated with expression of
genes associated with epithelial to mesenchymal transi-
tion. It is hoped that validation of results achieved in
Fisher et al. The EPMA Journal 2012, 3:1
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multiple gene algorithisms, which could be used to pre-
dict recurrence of RCC.
There is preliminary evidence that SNP genotyping
could be used to recognise SNP variants that influence
prognosis in patients with mRCC. In a study of 80
patients with mRCC, analysis of 21 NSPs within 13
cytokine genes revealed that heterozygosity for the IL-4
genotype -589C-33C resulted in a five-fold reduction in
median overall survival, compared with homozygotes for
IL-4 haplotype -589C-33C [143]. Another study identi-
fied three SNP polymorphisms in the VEGF gene asso-
ciated with survival [144], and in pazopanib-treated
patients, SNPs in genes related to angiogenesis, and
pazopanib mechanism of action and metabolism have
been associated with overall survival [145].
Finally, there are clinical and functional parameters
that may prove to be useful tools in predicting patient
outcomes and response to targeted treatments in
mRCC. Although retrospective, there is rather compel-
ling data demonstrating a consistent relationship
between hypertension induced by anti-VEGF treatments,
and improved clinical outcomes. In a retrospective
pooled analysis of four studies of sunitinib in mRCC,
patients who achieved a maximum systolic blood pres-
sure of 140 mmHg or higher had marked improvements
in objective response rates, progression-free and overall
survival, and a weaker association was observed in suni-
tinib-induced hypertension when defined by a maximum
diastolic blood pressure [146]. Similar results have been
reported in patients treated with axitinib and bevacizu-
mab [147,148]. There are obvious limitations to these
retrospective analyses, and a prospective study of first-
line axitinib (a newer multi-targeted TKI) will evaluate
the strategy of dose escalation of axitinib in the absence
of treatment-related hypertension or toxicity, on the
basis of a study demonstrating that hypertension and
axitinib drug levels are independently associated with
clinical outcome [149]. Furthermore, SNPs of VEGF and
VEGFR that predict the occurrence of hypertension in
patients receiving sunitinib have been proposed [150].
Early, small studies of treatment-induced radiographic
phenomena have shown promise but require much lar-
ger, prospective investigation. For example, changes in
tumour blood flow as measured by arterial spin labelling
magnetic resonance imaging (MRI) after 1 month of
treatment with PTK787, a small molecule VEGF inhibi-
tor, correlated with objective response at 4 months of
therapy [151]. An alternative functional MRI technique
found that the baseline volume transfer constant of the
contrast agent (Ktrans), indicating higher vascular per-
meability, correlated with subsequent progression free
survival on sorafenib, but changes in Ktrans during
treatment did not predict for clinical outcome [152].
In summary, there are no biomarkers that have been
approved for use in mRCC. Although the data described
above provides many promising leads, it is limited by
retrospective analyses, and inconsistencies in research-
based assays, which in turn depend on the method of
sample collection, processing and interpretation [131].
Drug resistance and molecular heterogeneity also impede
PPPM
Other challenges faced by clinicians and scientists in the
pursuit of personalised med i c i n ef o rm R C Ci n c l u d e
resistance to therapy and intra-tumoural heterogeneity.
Between a third and two-thirds of patients with mRCC
have tumours refractory to anti-VEGF and mTOR inhi-
bitor treatment from the outset, and all patients inevita-
bly acquire resistance to therapy [153]. There is an
increasing understanding of mechanisms of resistance,
which may include vascular resistance through activa-
tion of alternative pro-angiogenic pathways [154], and
hypoxia resistance [153]. Resistance to mTOR inhibition
is less well understood but preclinical models suggest
that negative feedback loops and parallel signalling path-
ways such as the Ras-mitogen-activated protein kinase
(MAPK) pathway play an important role [153]. Again,
routine tissue collection at important clinical time-
points (such as pre-treatment, and at the time of pro-
gressive disease) is likely to add to the mounting body
of evidence delineating resistance pathways. The Eur-
opean Union multi-disciplinary Personalised RNA Inter-
ference to Enhance the Delivery of Individualised
Cytotoxic and Targeted therapeutics (PREDICT) consor-
tium has identified four key areas of research, and
obstacles to individualised therapy in mRCC–these are
the identification of predictive and surrogate biomarkers,
determination of the mechanisms of resistance and
response to VEGF-targeted therapy, and the identifica-
tion of new targets [155]. It is hoped that these end-
points will be addressed through the analysis of tumour
tissue collected in pre-operative biopsy studies in
mRCC, using novel methods of personalise tumour-
derived small hairpin RNA and high-throughput small
interfering RNA screens.
Intratumour heterogeneity: a challenge to
personalised medicine and biomarker discovery
It is clear that the histological subtypes of RCC differ in
their molecular profiles, and systematic screens of genes
involved in RCC have revealed substantial genetic het-
erogeneity even within the clear cell subtype, previously
thought to be dominated by a mutation in a single gene,
VHL [37,156,157]. Furthermore, it is emerging that
intratumour heterogeneity exists. It is this which pre-
sents the biggest challenge to biomarker discovery in
RCC, and genetic instability may independently contri-
bute to multiple drug resistance [158,159].
Fisher et al. The EPMA Journal 2012, 3:1
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by fluorescence in situ hybridisation (FISH) for VHL
deletions, and confirmed that VHL deletions were pre-
sent in 69% of clear cell RCCs, consistent with previous
studies. However, within individual clear cell tumours,
subpopulations of cells with and without VHL deletion
existed, and VHL-depleted subpopula-tions had different
chromosome 3 counts [157]. The situation has become
much more complex since this study was published,
with the discovery of multiple genes implicated in RCC,
and there are intensive efforts underway to define the
clonal architecture of RCC tumours. This will require
multiple biopsies of individual primary and secondary
tumours; to date, there are no published data using this
approach in mRCC but it is a method being utilised in
the PREDICT consortium’s pre-operative trials of
mTOR and kinase inhibitors [155].
Conclusions and outlook
There have been significant developments in the treat-
ment of mRCC in recent years, but preventive, predic-
tive and personalised medicine for this condition
remains elusive. Failure to provide such tailored treat-
ment for patients clearly has profound clinical and social
implications for individuals but also impacts heavily on
health economies. Personalised medicine will not be
achieved unless there is an improved understanding of
the mechanisms which underpin response and resistance
to therapy, and biological markers of these processes. A
paradigm shift is required, in which clinicians select
treatments based on molecular, rather than anatomical
or histopathological criteria. After all, knowledge of
molecular pathways in RCC has led to the development
of the therapeutic agents which have already resulted in
vast improvements in clinical outcomes for patients.
However, enhanced understanding of comprehensive
molecular networks, and intra- and inter-tumour het-
erogeneity is the key to further improvements in the
treatment of mRCC. Clinical trial design will need to
adapt in order to achieve this goal; in particular, pre-
operative studies in this field offer a unique opportunity
for researching the biology of this complex malignancy.
Finally, this review has focussed on treatment of meta-
static RCC, and whilst it is clearly desirable to improve
survival and quality of life for those patients with
advanced disease, it is also true that overall improve-
ments in outcomes in this condition, as in other tumour
types, depends on superior treatment of early disease
and prevention of metastastic spread. Currently no stan-
dard adjuvant therapy exists for patients after nephrect-
omy for RCC, but there is no doubt that the progress
made in the field of metastatic RCC will translate into
more rational management of localised disease with
appropriate integration of surgical and medical therapy.
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